Targeted Drug Delivery Device Market Size to reach USD 2,153 million by 2035 | Roots Analysis

According to our latest market report "Targeted Drug Delivery Device Market" by Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035", the targeted drug delivery device market size is projected to reach USD 2,153 million by 2035 from USD 427 million in 2026, growing at a CAGR of 19.7% in the forecast period, till 2035.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/targeted-drug-delivery/request-quote.html


The pharmaceutical industry is increasingly moving towards biologics from traditional small molecule drugs. This is primarily because of the specificity and efficacy of biologics that makes them proficient in treating complex diseases. Since, it has become increasingly popular because it offers many benefits still biologics poses various challenges, such as drug delivery-related complications along with immunogenicity. To overcome these challenges, the pharmaceutical industry is focusing on the development of targeted drug delivery devices that will improve the therapeutic safety index and enhance the delivery of therapies to the targeted site. Targeted drug delivery device enables the administration of drugs to specific areas, thereby enhancing efficacy and reducing systemic toxicity. Site-specific drug delivery needs are one of the factors that push forward newer innovative drug delivery technologies and devices. Considering that biologics pose an inherent delivery challenge, there is a ongoing need for targeted drug delivery devices. Therefore, the companies are actively engaged in manufacturing targeted drug delivery devices that can optimize drug efficacy and safety.

To request a sample copy / brochure of this report, please visit:
https://www.rootsanalysis.com/reports/targeted-drug-delivery/request-sample.html

Targeted Drug Delivery Device Market Segments

Based on the type of device, the market is segmented into catheters, cannulas and others.

1. The cannula segment is likely to capture the largest revenue share of more than 90% in the targeted drug delivery device market, in 2026.
2. The catheter segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 23.5% during the forecast period.

Based on the target organ, the market is segmented into breast, brain, heart and eyes.

1. The breast segment is likely to capture the largest revenue share of close to 75% in the targeted drug delivery device market, in 2026.
2. The heart segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 23.5% during the forecast period.

Based on the type of therapy delivered, the market is segmented into immunotherapies, gene therapies and cell therapies.

1. The immunotherapies segment is likely to capture the largest revenue share of over 80% in the targeted drug delivery device market, in 2026.
2. The cell therapies segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 28.6% during the forecast period.

Based on the route of administration, the market is segmented into intratumorals, transendocardials and others.

1. The intratumorals segment is likely to capture the largest revenue share of over 80% in the targeted drug delivery device market, in 2026.
2. The others segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 30.4% during the forecast period.

Based on the therapeutic area, the market is segmented into oncological disorders, cardiovascular disorders, neurological disorders and ophthalmic disorders.

1. The oncological disorders segment is likely to capture the largest revenue share of over 80% in the targeted drug delivery device market, in 2026.
2. The cardiovascular disorders segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 23.5% during the forecast period.

Based on key geographical regions, the market is segmented North America, Europe and Asia-Pacific

1. North America dominated the targeted drug delivery device market and is likely to account for the largest revenue share of over 75% in 2026.
2. In Europe, targeted drug delivery device market is anticipated to demonstrate lucrative growth during the forecast period with a growth rate of 21.3%.

Targeted Drug Delivery Device Market Regional Outlook
Based on the key geographical regions, the targeted drug delivery device market can be segmented into three regions, including North America, Europe and Asia-Pacific. Led by the US, North America is anticipated to capture the majority share of the targeted drug delivery devices market in 2026 and this trend is likely to remain unchanged during the forecast period.

Key Report Takeaways
1. Presently, over 30 companies are engaged in manufacturing targeted drug delivery devices across the globe.
2. Over 50% of the players engaged in this domain are based in North America followed by 35% in Europe.
3. Currently, 286 clinical trials are ongoing that are focused on targeted drug delivery devices for stem cell therapies and gene therapies.
4. Targeted drug delivery devices delivering drugs directly to the breast capture 73% of the overall targeted drug delivery device market.
5. The global targeted drug delivery device market is anticipated to grow at a CAGR of 19.7%

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/targeted-drug-delivery.html

Targeted Drug Delivery Device Market Key Players
Examples of key companies engaged in targeted drug delivery device market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Alcyone Lifesciences, Algorae Pharmaceuticals, BioCradia, ClearPoint Neuro, Gloriana Therapeutics, Mercator MedSystems, Neurotech Pharmaceuticals, Novartis, OncoSec, PharmaCyte Biotech, PulseSight Therapeutics, Renishaw, Silexion Therapeutics and SmartCella

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way. dedicated to serve our clients in the best possible way.

This release was published on openPR.